We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Adherex Announces Patient Enrollment in Phase 2 Clinical Trial for Metastatic Breast Cancer

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Adherex Announces Patient Enrollment in Phase 2 Clinical Trial for Metastatic Breast Cancer"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Adherex Technologies Inc. has announced fifty percent (70/140) of the patients have been enrolled in the company's on-going Phase 2 clinical trial for Metastatic Breast Cancer.

The open-label study is comparing the antitumor activity and safety of completely oral Eniluracil plus 5-FU and Leucovorin regimen (Treatment Arm 1; n=80) versus Xeloda® (capecitabine) (Treatment Arm 2; n=60).

Eligible patients have been previously treated with an anthracycline and a taxane. Patients who have disease progression in Arm 2 may crossover to take Eniluracil plus 5-FU and Leucovorin (Treatment Arm X).

The eniluracil plus 5-FU and Leucovorin regimen has been active and generally well-tolerated in both Arm 1 and Arm X.

Adherex anticipates enrollment of all 140 patients during the third quarter of this year and final data for progression-free survival by first quarter of 2013.

The statistical comparison of Treatment Arms 1 and 2 will occur after the study has been completed.

"I am pleased to see the progress of this study," said Edgardo Rivera, MD, National Prinicipal Investigator for the trial and medical director at Banner MD Anderson Cancer Center in Gilbert, Ariz. "I am looking forward to reviewing the results of this trial with the goal of improving breast cancer treatment and survivor rates."